Stock ALCAR CARMAT
Add to a list
To use this feature you must be a member
Log inSign up

Financials CARMAT

Equities

ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris
Other stock markets
 16:35:24 26/04/2024 BST 		5-day change 1st Jan Change
3.15 EUR -2.63% Intraday chart for CARMAT -17.21% -52.99%
03-25 Carmat: final agreement with creditors CF
03-25 Carmat Secures Two-year Extensions for Bank Loans MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 211.8 242.7 358.5 312.3 204.6 78.06 78.06 -
Enterprise Value (EV) 1 191.2 203.6 361.4 325.1 208.5 165.8 147 190.1
P/E ratio -5.22 x -5.7 x -9.93 x -5.13 x -4.4 x -1.52 x -2.66 x -3.44 x
Yield - - - - - - - -
Capitalization / Revenue - 347 x - 142 x 682 x 59.2 x 3.39 x 1.93 x
EV / Revenue - 291 x - 148 x 695 x 59.2 x 6.38 x 4.69 x
EV / EBITDA -4.65 x -4.94 x -13.1 x -6.37 x -4.15 x -2.97 x -4.74 x -13.4 x
EV / FCF -4.72 x -4.98 x -6.65 x -5.25 x -3.71 x -3.13 x -2.74 x -5.29 x
FCF Yield -21.2% -20.1% -15% -19% -26.9% -32% -36.4% -18.9%
Price to Book 29.1 x 6.24 x 47.2 x 330 x 14.3 x -1.9 x -1.19 x -0.78 x
Nbr of stocks (in thousands) 9,014 12,590 12,667 15,349 19,615 24,782 24,782 -
Reference price 2 23.50 19.28 28.30 20.35 10.43 3.150 3.150 3.150
Announcement Date 13/02/19 12/02/20 10/02/21 16/02/22 23/02/23 24/04/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - 0.7 - 2.2 0.3 2.8 23.05 40.52
EBITDA 1 -41.13 -41.23 -27.58 -51.08 -50.24 -43.03 -31 -14.15
EBIT 1 -42.77 -42.4 -36.4 -52.4 -51.9 -52.5 -45.2 -36.61
Operating Margin - -6,057.14% - -2,381.82% -17,300% -1,875% -196.07% -90.34%
Earnings before Tax (EBT) 1 -43.71 -44.2 -38.9 -63.74 -55.77 -57.61 -56.31 -46.89
Net income 1 -41.73 -42.6 -37 -61.9 -53.7 -53.9 -38 -32.05
Net margin - -6,085.71% - -2,813.64% -17,900% -1,925% -164.84% -79.1%
EPS 2 -4.500 -3.380 -2.850 -3.970 -2.370 -2.069 -1.185 -0.9150
Free Cash Flow 1 -40.47 -40.89 -54.37 -61.93 -56.12 -40.83 -53.55 -35.95
FCF margin - -5,841.96% - -2,815.09% -18,707.67% -503.92% -232.32% -88.71%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 13/02/19 12/02/20 10/02/21 16/02/22 23/02/23 24/04/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 Q1 2021 Q2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 S2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 S2 2025 S1 2025 S2
Net sales 1 - - - - - 1.1 1.1 2.2 0.06 0.06 - - 0.3 0.6 5.5 8 5.05 - - 5.49 - 12.61 21.92 35.39
EBITDA - - - - - - - - - - - - - - - - - - - - - - - -
EBIT 1 -20.6 -15.8 -12.77 -12.77 -25.5 -13.38 -13.38 -26.9 -12.54 -12.54 -25.1 - -26.8 - -12.56 -10.06 -33.37 - - -26.1 - -25.99 -23.54 -18.88
Operating Margin - - - - - -1,216.36% -1,216.36% -1,222.73% -20,900% -20,900% - - -8,933.33% - -228.45% -125.81% -660.79% - - -475.41% - -206.11% -107.39% -53.35%
Earnings before Tax (EBT) 1 -21.61 -17.3 -13.51 -13.51 - -18.39 -18.39 -36.71 -13.47 -13.47 -26.9 - - - -13.52 -11.02 -35.46 - - -28.11 - -28.21 -25.71 -21.18
Net income 1 -20.8 -16.2 -13.18 -13.18 -26.4 -17.77 -17.77 -35.5 -13 -13 -26 - - -26.7 -13.52 -11.02 -31.98 - - -24.69 - -24.79 -23.79 -19.27
Net margin - - - - - -1,615.45% -1,615.45% -1,613.64% -21,666.67% -21,666.67% - - - -4,450% -245.73% -137.69% -633.27% - - -449.73% - -196.59% -108.53% -54.45%
EPS 2 - - - - -1.713 -1.140 -1.140 -2.257 - - - - - - -0.5900 -0.4400 -1.230 -0.3000 -0.2300 -0.8200 -0.1500 -0.7300 -0.6600 -0.4800
Dividend per Share - - - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 09/09/20 10/02/21 15/09/22 15/09/21 15/09/21 15/09/22 16/02/22 16/02/22 15/09/22 15/09/22 15/09/22 23/02/23 23/02/23 25/09/23 - - - - - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - 2.96 12.8 3.9 49.6 68.9 112
Net Cash position 1 20.7 39.1 - - - - - -
Leverage (Debt/EBITDA) - - -0.1072 x -0.2506 x -0.0776 x -1.153 x -2.223 x -7.919 x
Free Cash Flow 1 -40.5 -40.9 -54.4 -61.9 -56.1 -40.8 -53.6 -36
ROE (net income / shareholders' equity) -162% -143% - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 0.8100 3.090 0.6000 0.0600 0.7300 -1.660 -2.650 -4.030
Cash Flow per Share 2 -4.190 -3.190 -4.010 -3.240 -2.400 -1.900 -1.030 -0.7400
Capex 1 2.29 0.65 2.33 1.76 1.75 2.85 3.23 3.48
Capex / Sales - 92.68% - 80.14% 582.67% 35.17% 14.03% 8.57%
Announcement Date 13/02/19 12/02/20 10/02/21 16/02/22 23/02/23 24/04/24 - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for CARMAT

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.15 EUR
Average target price
14.22 EUR
Spread / Average Target
+351.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
CARMAT Stock CARMAT
-52.99% 83.34M
STRYKER CORPORATION Stock Stryker Corporation
+12.07% 128B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.04% 10.65B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+0.91% 8.82B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+16.72% 7.19B
GLAUKOS CORPORATION Stock Glaukos Corporation
+25.15% 4.99B
AXONICS, INC. Stock Axonics, Inc.
+7.17% 3.4B
ENOVIS CORPORATION Stock Enovis Corporation
-1.36% 3.03B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-8.73% 2.14B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-10.15% 2B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. ALCAR Stock
  4. Financials CARMAT